Overview
Biorasi, LLC announced the completion of a majority investment by Riordan, Lewis & Haden Equity Partners (“RLH”) on November 16, 2018.
Headquartered in Miami, Florida, Biorasi is a full-service CRO with regional offices in Western and Eastern Europe, India, and Japan.
RLH, an investment firm headquartered in Los Angeles, California, is focused on building market-leading companies in healthcare, business services, and government services through organic growth
Significance
Biorasi is a new kind of CRO that brings a disruptive approach to a traditionally conservative industry. By focusing on project management optimization while incorporating a technology-enabled structured methodology, the Company is able successfully execute complex, challenging Phase I – IV trials faster, more efficiently, and with higher quality results than traditional CROs.
Biorasi, already one of the fastest growing CROs, expects that this investment will fuel years of continued growth and innovation.
Crosstree’s Role
Crosstree Capital Partners acted as the exclusive financial advisor to Biorasi.
Latest Deals
Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US
.V3%20(1).png)
Calyx has divested its 'Enterprise Technology' Division to Ennov, to Enhance Ennov’s portfolio of eClinical and eRegulatory Software Solutions
%20(1).png)
physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research
.png)
Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities
%20(NEW).png)
Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally
.png)
Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering
Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities
Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities
VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities
Grant Avenue Capital Recapitalizes CREO
Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform
SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU
Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings
Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities
Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities
Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities
ClinChoice Acquires CROMSOURCE to Expand CRO Capabilities Globally
anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally
OpenClinica Completes Growth Recapitalization with Thompson Street Capital Partners to Accelerate Enablement of Clinical Trials
